Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 9

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 9
---
 also intend to offer a license for our TAEUS technology to original equipment manufacturers (“OEMs”), such as ultrasound and thermoablative capital equipment makers, for incorporation in their new products. We believe that our TAEUS technology has the potential to add a number of new capabilities to conventional ultrasound and other types of capital equipment, thereby enhancing the utility and extending the use of these technologies to circumstances that either currently require the use of expensive CT or MRI imaging systems, where imaging is not practical using existing technology, or where other assessment tools such as surgical biopsy are required. To demonstrate the capabilities of our TAEUS platform, we have conducted various internal ex-vivo laboratory experiments and limited internal in-vivo large animal studies. In our ex-vivo and in-vivo testing, we have demonstrated that the TAEUS platform has multiple capabilities and potential clinical applications, including enhanced ultrasound for the early detection and staging of certain liver diseases and cancer, the real-time visualization of tissue temperature, and blood vessel and blood flow visualization. As of the date of this prospectus, no revenue has been generated by our TAEUS technology, which we have not commercially sold as of such date. While we received CE mark approval for our TAEUS FLIP (Fatty Liver Imaging Probe) application in March 2020, our TAEUS liver device does not have approval for marketing from the U.S. Food and Drug Administration. TAEUS Liver Device ENDRA’s first clinical product is designed to interface with a conventional ultrasound scanner, utilizing the scanner’s B-mode imaging to guide the selected region for assessment of liver fat content. The following sub-systems will comprise ENDRA’s first generation product.

| ● | Energy                                                                                      
 Generation: The RF source consists of a low power waveform generator and a high gain        
 amplifier. Together, these components generate the characteristic pulses of energy required 
 to excite thermoacoustic signals in tissue.                                                 |

| ● | Energy                                                                                    
 Delivery into Tissue: The RF applicator transmits pulses of energy generated by the RF    
 source into tissue. The applicator is positioned at the skin surface in proximity to the  
 target region for measurement and is designed to efficiently couple pulsed RF energy into 
 target tissues.                                                                           |

| ● | Signal                                                                                         
 Detection: A “receive only” ultrasound transducer specifically designed and                    
 optimized for thermoacoustic imaging. The transducer sub-system detects thermoacoustic signals 
 induced by the RF source within tissue. The transducer assembly is connected to high-speed     
 electronics for